Study published in the American Journal of Transplantation

BRISBANE, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces the publication of data demonstrating the clinical utility of measuring AlloSure in repeat kidney transplant recipients in the American Journal of Transplantation.

AlloSure is the first donor-derived cell-free DNA test to assess allograft health and is broadly available to transplant patients. Previous publications demonstrating the clinical value of AlloSure were based on first-time or single kidney transplant recipients (SKTR); the current study is the first study to include repeat kidney transplant recipients (RKTR).

“A significant percentage of patients require repeat kidney transplants and are at a higher risk for rejection,” said Roslyn Mannon, M.D., Professor of Medicine and Surgery at the University of Alabama at Birmingham. “There is an unmet need for a non-invasive diagnostic test to help clinicians closely monitor and optimize care for these patients. We are glad to see AlloSure demonstrate significant clinical utility in this population.”

Key highlights from the study:

• In patients without evidence of rejection, the median readouts of AlloSure were significantly lower than threshold levels for rejection in both SKTR and RKTR
• In patients with active rejection, AlloSure levels were similarly elevated in SKTR and RKTR patients alike

“CareDx believes in personalizing healthcare for all kidney transplant patients including those at high risk. This peer-reviewed publication supports the expanded clinical utility of AlloSure to include repeat kidney transplant recipients,” said James Yee, M.D., Ph.D., Executive Vice President and Chief Medical Officer at CareDx, Inc.

Full Reference: Repeat kidney transplant recipients with active rejection have elevated donor‐derived cell‐free DNA. Mannon RB, et al. American Journal of Transplantation. Published Online: 23 November 2018.

DOI: https://doi.org/10.1111/ajt.15192

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.

For more information, please visit: www.CareDx.com.

CONTACTS:
Media Relations
Amy Wheeler
Lazar Partners
646-871-8486
[email protected]

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
[email protected]